[Evaluation of the cost of treatment for terminal chronic renal insufficiency. Thoughts on the value of this type of study and the role of the nephrologist]

Abstract

To assess the cost of end stage renal failure treatment was the target of studies we achieved during the last ten years. We showed how much the global cost was favourably influenced by the number of available therapeutic methods. In a recent study, reported here, we followed a new methodology more often used today in our public hospitals. The comparison of analytical accountancy data with computerized medical informations as given by identification of Diagnosis Related Groups probably allows better assessment of "real cost". But is this approach really useful for nephrologists? These frequently asked questions cannot be performed without the participation of physicians. The question remains whether or not these studies will contribute to improve the quality of care and to allow some saving. We also hope sharing with readers of "Nephrologie" these kinds of considerations as well as our opinions and doubts.